FLT3 and acute myeloid leukemia: The combination of Quizartinib, Decitabine, and Venetoclax was studied in Phase I/II trial in a small group of patients with ND, unfit for intensive therapy, and R/R FLT-3 m AML with excellent CR/CRi rates (100% in ND and 78% in R/R) [31].